Pharmacokinetic Study of Primaquine and Pyronaridine-Artesunate in Healthy Subjects
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The observed changes of P. falciparum sensitivity to artemisinin lead to the intensification
of early detection as well as treatment monitoring in malaria infection. It is widely
accepted that the development of resistance can be delayed by the use of combination therapy,
especially combinations that include artemisinin derivatives (acts). As the resistance
problem is considered extremely serious; as a consequence, who has recommended that all
monotherapy for malaria should be stopped.
Current WHO guidelines recommend that the drug combination regimens using ACT with effective
partner medicines should be used to decrease the risk of development or spreading of
artemisinin resistance.